Combination Treatment of S-1 With Paclitaxel Versus Paclitaxel+Cisplatin and 5-Fu+Cisplatin as First-line Treatment in Advanced Esophageal Cancer

Trial Profile

Combination Treatment of S-1 With Paclitaxel Versus Paclitaxel+Cisplatin and 5-Fu+Cisplatin as First-line Treatment in Advanced Esophageal Cancer

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Fluorouracil; Paclitaxel
  • Indications Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 Status changed from recruiting to discontinued.
    • 29 Mar 2016 Planned primary completion date changed from 1 Jul 2013 to 1 Dec 2017, according to ClinicalTrials.gov record.
    • 28 Mar 2016 Planned End Date changed from 1 Jul 2013 to 1 Dec 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top